Search Results

Abilita Bio, a leader in enabling the discovery of membrane protein-targeted therapeutics, announced today the company changed its name to Abilita Therapeutics.

At a satellite kickoff event to the annual BIO meeting, investment bankers and VCs gave reasons for optimism amid a ‘volatile’ period for the industry.

The 2025 BIO International Convention (BIO2025), the world’s largest annual biotech event, will take place from June 16 to 19 (U.S. time) at the Boston Convention & Exhibition Center. This year, Taipei City Government is partnering with six Taipei-based biotech companies, including PanCAD.ai Co., Ltd., Instant NanoBiosensors Co., Ltd., Bened Biomedical Co., Ltd., Cancer Free Biotech Ltd., Xantho Biotechnology Co., Ltd., and Energenesis Biomedical Co., Ltd., to showcase their innovations at the Taiwan Pavilion (Booth #1645) in the Taipei Exhibition Area.

Robert F. Kennedy Jr. testified in front of largely combative congresspeople on vaccine policy, his MAHA report and more; the mass leadership exodus at the FDA continues as CDER and CBER shed key staff; Kennedy’s revamped CDC vaccine advisors convene for their first meeting; Novo and Lilly present new data at the American Diabetes Association’s annual meeting; and BioSpace recaps BIO2025.

GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.

Led by alums from Takeda and Boston Pharmaceuticals, Hillstar Bio is working on treatments that remove harmful immune cells to relieve disease.

Abilita Bio, Inc., today announced the appointment of Daniel M. Bradbury to its Board of Directors.